{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:52:53Z","timestamp":1791622373153,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","award":["US-TYS-12210"],"award-info":[{"award-number":["US-TYS-12210"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.msard.2024.106236","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T13:34:05Z","timestamp":1735047245000},"page":"106236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-0538","authenticated-orcid":false,"given":"Clare McGarvey","family":"Lambert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimoor","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E","family":"Longbrake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.106236_bib0001","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","article-title":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study","volume":"48","author":"Boleto","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.msard.2024.106236_bib0002","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585231208311","article-title":"Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity","volume":"30","author":"Bou Rjeily","year":"2024","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.106236_bib0003","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2024.106236_bib0004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.msard.2024.106236_bib0005","doi-asserted-by":"crossref","unstructured":"Fox, E.J. et al. Lymphocyte counts and infection rates Long-term fingolimod treatment in primary progressive MS Class of Evidence Criteria for rating therapeutic and diagnostic studies. 6, (2019).","DOI":"10.1212\/NXI.0000000000000614"},{"key":"10.1016\/j.msard.2024.106236_bib0006","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/13524585211037909","article-title":"Multiple sclerosis MSJ journal long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results","author":"Gold","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.106236_bib0007","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.27026","article-title":"Hospital-treated infections and risk of disability worsening in multiple sclerosis","volume":"96","author":"Hu","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.106236_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104245","article-title":"Serious infections in patients with relapsing and progressive forms of multiple sclerosis: a German claims data study","volume":"68","author":"Knapp","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106236_bib0010","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2024.106236_bib0011","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1177\/1352458517707069","article-title":"Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count","volume":"24","author":"Longbrake","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.106236_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2024.106236_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103921","article-title":"Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab","volume":"63","author":"Nicholas","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106236_bib0014","unstructured":"NIH: Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40 (2021)."},{"key":"10.1016\/j.msard.2024.106236_bib0015","doi-asserted-by":"crossref","unstructured":"Peters, J. & Longbrake, E.E. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease HHS Public Access. doi:10.1016\/j.msard.2022.104400.","DOI":"10.1016\/j.msard.2022.104400"},{"key":"10.1016\/j.msard.2024.106236_bib0016","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrneurol.2015.14","article-title":"Multiple sclerosis\u2014a quiet revolution","volume":"11","author":"Ransohoff","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2024.106236_bib0017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"1940","journal-title":"Curr. Treat. Options. Neurol."},{"key":"10.1016\/j.msard.2024.106236_bib0018","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis data from 2 different national strategies supplemental content CME Quiz at jamacmelookup.com and CME Questions page 1280","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2024.106236_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.799138","article-title":"Evolution of disease modifying therapy benefits and risks: an argument for de-escalation as a treatment paradigm for patients with multiple sclerosis","volume":"12","author":"Vollmer","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.106236_bib0020","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1177\/1352458516681198","article-title":"Infection-related health care utilization among people with and without multiple sclerosis","volume":"23","author":"Wijnands","year":"2017","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2024.106236_bib0009","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00109-019-01761-5","article-title":"Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis","volume":"97","author":"Yadav","year":"2019","journal-title":"J. Mol. Med. (Berl)"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824008125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824008125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T21:02:59Z","timestamp":1739480579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824008125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":20,"alternative-id":["S2211034824008125"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106236","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106236"}}